Molbio Diagnostics IPO 2026: Price, Dates and Business Review

The Molbio Diagnostics IPO opens for subscription today, 10 August 2026, alongside the Dhoot Transmission issue, making today one of the busiest days of the current primary market calendar. The Molbio Diagnostics IPO is priced at Rs 768 to Rs 807 per share, with a lot size of 18 shares and a minimum retail investment of Rs 14,526 at the upper price band. The issue will remain open until August 12, 2026, with allotment expected on August 13 and shares tentatively scheduled to list on BSE and NSE on August 17, 2026.

Click Here – Get Free Investment Predictions

The Molbio Diagnostics IPO is a Rs 939.70 crore issue comprising a fresh issue of Rs 200 crore and an offer for sale of 91.66 lakh shares worth approximately Rs 739.70 crore. The company is backed by global investor Temasek and Motilal Oswal Private Equity, providing institutional validation for the business. Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are the book-running lead managers. KFin Technologies is the registrar.

Molbio Diagnostics IPO: Key Details

Particulars	Details
Issue Size	Rs 939.70 crore
Fresh Issue	Rs 200 crore
Offer for Sale	91.66 lakh shares (~Rs 739.70 crore)
Price Band	Rs 768 to Rs 807 per share
Face Value	Re 1 per share
Lot Size	18 shares (min retail: Rs 14,526)
Open / Close	10 August to 12 August 2026
Allotment	13 August 2026
Listing	17 August 2026 (NSE and BSE)
Investors	Temasek, Motilal Oswal Private Equity
Lead Managers	Kotak, IIFL Capital, Jefferies, Motilal Oswal

About Molbio Diagnostics: Truenat and Point-of-Care Testing

Molbio Diagnostics is a Goa-based point-of-care diagnostics company that develops and manufactures diagnostic testing devices and test kits for detecting infectious and other diseases. Its flagship product is the Truenat platform, a portable molecular diagnostic device that delivers results in approximately an hour and has received World Health Organization endorsement for tuberculosis diagnosis. The Molbio Diagnostics IPO offers investors access to a company operating at the intersection of molecular diagnostics, healthcare access and global infectious disease response.

The company's manufacturing installed capacity stands at 5,400 devices per annum and 3.9 crore Truenat test kits annually. Molbio Diagnostics has a presence in more than 90 countries, with its customer base spanning government health programmes, hospitals, diagnostic laboratories and international development organisations. The global footprint gives the Molbio Diagnostics IPO a differentiated positioning relative to purely India-focused diagnostics companies.

Screen Molbio Diagnostics and Healthcare Sector Stocks on Univest

Molbio Diagnostics Financial Performance

The Molbio Diagnostics IPO is supported by strong recent financial growth. Revenue from operations stood at approximately Rs 1,445 crore in FY26, up 41.7 percent from Rs 1,027.94 crore in FY25. Net profit rose 14.8 percent to approximately Rs 164-166 crore in FY26 from Rs 138.58 crore a year earlier. The revenue growth materially outpaced profit growth, suggesting that the company is investing in capacity and capability expansion, which is consistent with the planned use of fresh issue proceeds.

The OFS component of the Molbio Diagnostics IPO (approximately Rs 739.70 crore) is significantly larger than the fresh issue (Rs 200 crore), meaning most of the capital raised will flow to selling shareholders rather than the company itself. Promoter holding will come down from 46.65 percent to 43.01 percent post-issue.

Use of Fresh Issue Proceeds

From the Rs 200 crore fresh issue, the Molbio Diagnostics IPO will deploy Rs 105.5 crore toward establishing a research and development facility, Centre of Excellence and office infrastructure through its wholly owned subsidiary Bigtec. A further Rs 72.2 crore will fund the purchase of plant, machinery and equipment for manufacturing units in Goa and Visakhapatnam. The balance will be used for general corporate purposes.

Key Risks

The Molbio Diagnostics IPO comes with sector-specific risks. Diagnostics demand can be lumpy, with significant dependence on government procurement decisions and public health programme funding, particularly for infectious disease testing. Competition from global diagnostic majors with larger R&D budgets represents a structural risk to the company's long-term pricing power. The company's high dependence on the Truenat platform means any technological disruption or competing platform that achieves WHO endorsement could erode its market position. Investors should read the risk factors in the Red Herring Prospectus carefully before applying for the Molbio Diagnostics IPO.

Grey market premium data circulates informally for IPOs but is not published, verified or endorsed by SEBI, NSE or BSE. It is not always accurate and should not be the basis for investment decisions. For GMP updates, readers are advised to check dedicated IPO tracking platforms and verify the information independently.

Download the Univest iOS App or Univest Android App to track the Molbio Diagnostics IPO subscription, allotment and listing on Univest.

Conclusion

The Molbio Diagnostics IPO opens today on 10 August 2026, giving retail investors access to a Goa-based diagnostics company with a WHO-endorsed TB testing platform and a presence in over 90 countries. The Rs 939.70 crore issue is backed by Temasek and Motilal Oswal Private Equity. With FY26 revenue growth of 41.7 percent and a clear plan for using fresh issue proceeds to build R&D and manufacturing capacity, the Molbio Diagnostics IPO presents a differentiated healthcare play in the current IPO market. Always read the RHP and consult a SEBI-registered advisor before investing.

What is the Molbio Diagnostics IPO price band?

Ans. The Molbio Diagnostics IPO price band is Rs 768 to Rs 807 per share with a face value of Re 1 per share.

What is the Molbio Diagnostics IPO lot size?

Ans. The Molbio Diagnostics IPO lot size is 18 shares. The minimum retail investment is Rs 14,526 at the upper price band of Rs 807. Retail investors can apply for up to 13 lots (234 shares).

When does the Molbio Diagnostics IPO close and when will it list?

Ans. The Molbio Diagnostics IPO closes on 12 August 2026. Allotment is expected on 13 August 2026. Shares are tentatively scheduled to list on BSE and NSE on 17 August 2026.

What is Molbio Diagnostics and what is the Truenat platform?

Ans. Molbio Diagnostics is a Goa-based point-of-care diagnostics company. Its flagship Truenat platform is a portable molecular diagnostic device endorsed by WHO for tuberculosis diagnosis that delivers results in approximately one hour.

Who are the investors in Molbio Diagnostics?

Ans. Molbio Diagnostics is backed by Temasek, the Singapore-based global investment firm, and Motilal Oswal Private Equity, both of which are existing shareholders participating in the offer for sale component of the Molbio Diagnostics IPO.

What will the fresh issue proceeds be used for?

Ans. From the Rs 200 crore fresh issue, Rs 105.5 crore will fund an R&D and Centre of Excellence facility through subsidiary Bigtec, and Rs 72.2 crore will purchase plant and equipment for manufacturing in Goa and Visakhapatnam.

How do I apply for the Molbio Diagnostics IPO?

Ans. You can apply for the Molbio Diagnostics IPO through the ASBA facility via your bank's internet banking platform or UPI-enabled stockbroker apps from 10 August to 12 August 2026.